C4 Therapeutics, Inc. (CCCC) stock
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/302% below fair value
$2.48−0.05 (-2.17%)
Close on Nov 18, 2026Market cap $304.49MP/E –Yield –
C4 Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
C4 Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$85.39M. For fiscal 2025 it was -$99.30M. The highest annual figure on record is $54.27M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$99.30M | – |
| FY2024 | Dec 31, 2024 | -$65.34M | – |
| FY2023 | Dec 31, 2023 | -$108.55M | – |
| FY2022 | Dec 31, 2022 | -$111.44M | – |
| FY2021 | Dec 31, 2021 | -$88.24M | – |
| FY2020 | Dec 31, 2020 | -$67.90M | -225.1% |
| FY2019 | Dec 31, 2019 | $54.27M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.61M | – |
| Q1 FY2026 | Mar 31, 2026 | -$30.01M | – |
| Q4 FY2025 | Dec 31, 2025 | -$22.16M | – |
| Q3 FY2025 | Sep 30, 2025 | -$31.62M | – |
| Q2 FY2025 | Jun 30, 2025 | -$12.24M | – |
| Q1 FY2025 | Mar 31, 2025 | -$33.29M | – |
| Q4 FY2024 | Dec 31, 2024 | -$17.93M | – |
| Q3 FY2024 | Sep 30, 2024 | -$24.12M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.17M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.12M | – |
| Q4 FY2023 | Dec 31, 2023 | -$24.17M | – |
| Q3 FY2023 | Sep 30, 2023 | -$31.31M | – |
| Q2 FY2023 | Jun 30, 2023 | -$19.36M | – |
| Q1 FY2023 | Mar 31, 2023 | -$33.71M | – |
| Q4 FY2022 | Dec 31, 2022 | -$30.62M | – |
| Q3 FY2022 | Sep 30, 2022 | -$31.33M | – |
| Q2 FY2022 | Jun 30, 2022 | -$22.72M | – |
| Q1 FY2022 | Mar 31, 2022 | -$26.77M | – |
| Q4 FY2021 | Dec 31, 2021 | -$25.78M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.36M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.75M | – |
| Q1 FY2021 | Mar 31, 2021 | -$25.36M | – |
| Q4 FY2020 | Dec 31, 2020 | -$21.88M | – |
| Q3 FY2020 | Sep 30, 2020 | -$14.68M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.49M | – |
| Q1 FY2020 | Mar 31, 2020 | -$16.85M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.23M | – |
See a number that looks wrong?